Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients

Table 3 Comparison of PM/Scl-100 antibody-positive versus-negative patients

Disease manifestation	anti-PM/Scl-100-positive (n = 20)	anti-PM/Scl-100-negative (n = 261)	P value	Sensitivity, percentage^a	Specificity, percentage^b
Digital ulcers^c	12 (60.0)	100 (38.5)	0.095	10.7	95.2
Lung fibrosis^c	11 (55.0)	87 (33.5)	0.086	11.2	95.1
CK elevation^c	7 (35.0)	30 (11.5)	0.009	18.9	94.7
Esophago-gastral involvement^c	11 (55.0)	204 (78.5)	0.026	5.1	86.2
Small intestinal involvement^c	3 (15.0)	100 (38.5)	0.052	2.9	90.4
Colon involvement^c	4 (20.0)	115 (44.2)	0.037	3.4	90.1

Clinical differences between antibody-positive and -negative patients were shown only when P values of below 0.1 were detected. ^a,bCalculations of sensitivity and specificity are analogous to those in Table 2. ^cValues displayed are numbers of patients (percentages). CK, creatine kinase.

ISSN: 1478-6362